 |
Ublituximab in combination with phosphoinositide-3-kinase (PI3K) delta inhibitor |
|---|---|
| Trade Name | |
| Orphan Indication | Diffuse Large B-cell Lymphoma |
| USA Market Approval | USA |
| USA Designation Date | 2017-01-19 00:00:00 |
| Sponsor | TG Therapeutics, Inc.;2 Gansevoort Street, 9th Floor;New York, New York, 10014 |
